Please assess the completion status of the following clinical trial:

Trial Title: Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 years and older. The lower age limit may be higher if legally required in the participating country~* Women of childbearing potential can only be included in the study if a pregnancy test is negative and if they agree to use adequate contraception when sexually active~* Subjects with worsening chronic heart failure requiring emergency presentation to hospital and treatment with intravenous diuretics at hospital~* Subjects with clinical diagnosis of chronic heart failure (CHF) either ischemic or non ischemic, New York Heart Association (NYHA) functional class II-IV~* Subjects with type 2 diabetes mellitus and / or~* Subjects with 30 mL/min/1.73m\^2 \</= eGFR \</= 60 mL/min/1.73m\^2 (MDRD, Modification of Diet in Renal Disease Study Group) at screening~* Left ventricular ejection fraction (LVEF) \</= 40%~* Blood potassium \</= 5.0 mmol/L at screening~* Systolic blood pressure \>/= 90 mmHg without signs and symptoms of hypotension at the screening visit~Exclusion Criteria:~* Acute de-novo heart failure or acute inflammatory heart disease, e.g. acute myocarditis~* Acute coronary syndrome (ACS) in last 30 days prior to screening~* Cardiogenic shock~* Valvular heart disease requiring surgical intervention during the course of the study~* Stroke or transient ischemic cerebral attack in the last 3 months prior to the screening visit~* Concomitant treatment with any mineralocorticoid receptor antagonist (MRA), renin inhibitor, or potassium-sparing diuretic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Finerenone(BAY94-8862)[2.5mg] + Placebo (Type: EXPERIMENTAL): Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
- Finerenone (BAY94-8862)[5mg] + Placebo (Type: EXPERIMENTAL): Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
- Finerenone (BAY94-8862)[7.5mg] + Placebo (Type: EXPERIMENTAL): Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
- Finerenone (BAY94-8862)[10mg] + Placebo (Type: EXPERIMENTAL): Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
- Finerenone (BAY94-8862)[15mg] + Placebo (Type: EXPERIMENTAL): Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
- Eplerenone [25 mg] + Placebo (Type: ACTIVE_COMPARATOR): Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).